Skip Navigation

Innovations

  • Our Mission

    To actively accelerate innovations to benefit patients, society, and the Dana-Farber Cancer Institute. We team with investigators to identify new discoveries and generate alliances to move science from bench to clinic for maximum impact.

    Our Vision

    To spark and fuel a spirit of innovation across the organization by providing effective tools to continuously question, create, and imagine what else might be possible.

    Collaboration Opportunities

    In collaborating with Dana-Farber, your organization will have access to the Institute's specialized expertise, and to the unique array of core facilities needed to explore new areas of research. Learn more about Dana-Farber Centers that are interested in partnering with industry. Explore Dana-Farber's extensive Core Facilities. And discover more opportunities to collaborate.

  • BODFI statistics for 2019
  • In partnership with the Innovation Office, Dana-Farber makes publicly available a list of FDA-approved therapeutics and diagnostics in which the Institute has a financial interest.
    View the list

  • Technology News

    loren-walensky

    Loren D. Walensky, MD, PhD, Named Top Translational Researcher of 2019 by Nature

    Nature Biotechnology recently named Dana-Farber's Loren D. Walensky, MD, PhD, a top translational researcher of 2019. Nature's nomination was based on total patents (European and US) granted for the year. Nature also shared that Dr. Walensky's top cited patent between 2015 and 2019 is US9273099, ‘Stabilized Alpha Helical Peptides And Uses Thereof’ with 23 total citations.

    Otto Metzger

    Genetic Test Identifies Patients with Invasive Lobular Breast Cancer at High Risk of Disease Recurrence

    Dana-Farber investigators share in a new study a test that scans the activity of 70 genes in breast cancer tissue, which can help identify patients with invasive lobular carcinoma (ILC) who have a high risk of the cancer recurring or progressing after surgery. The findings, based on an international clinical trial known as MINDACT involving nearly 500 women with ILC, were presented by Dana-Farber's Otto Metzger, MD, at the European Breast Cancer Conference (EBBC) in October. 

    Myles_Brown_SOG_3742_15

    Myles Brown, MD, Elected to the National Academy of Medicine

    The National Academy of Medicine (NAM) has announced the election of Myles Brown, MD, Director of Dana-Farber's Center for Functional Cancer Epigenetics, during its annual meeting, alongside 90 regular members and 10 international members. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. 


    Coming Soon: Our Quarterly Newsletter

    Stay current with Dana-Farber technology news, transactions, patents, publications, events, and more.